CoChat

Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

Open access
Alagesan, Brinda, Contino, Gianmarco, Guimaraes, Alexander R., Corcoran, Ryan B., Deshpande, Vikram, Wojtkiewicz, Gregory R., Hezel, Aram F., Wong, Kwok-Kin, Loda, Massimo, Weissleder, Ralph, Benes, Cyril, Engelman, Jeffrey A., Bardeesy, Nabeel · 2015 · Clinical Cancer Research
Cited by 144

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Purpose: Improved therapeutic approaches are needed for the treatment of pancreatic ductal adenocarcinoma (PDAC). As dual MEK and PI3K inhibition is presently being used in clinical trials for patients with PDAC, we sought to test the efficacy of combined targeting of these pathways in PDAC using both in vitro drug screens and genetically engineered mouse models (GEMM). Experimental Design: We performed high-throughput screening of >500 human cancer cell lines (including 46 PDAC lines), for sensitivity to 50 clinically relevant compounds, including MEK and PI3K inhibitors. We tested the top hit in the screen, the MEK1/2 inhibitor, AZD6244, for efficacy alone or in combination with the PI3K inhibitors, BKM120 or GDC-0941, in a KrasG12D-driven GEMM that recapitulates the histopathogenesis of human PDAC. Results: In vitro screens revealed that PDAC cell lines are relatively resistant to single-agent therapies. The response profile to the MEK1/2 inhibitor, AZD6244, was an outlier, showing the highest selective efficacy in PDAC. Although MEK inhibition alone was mainly cytostatic, apoptosis was induced when combined with PI3K inhibitors (BKM120 or GDC-0941). When tested in a PDAC GEMM and compared with the single agents or vehicle controls, the combination delayed tumor formation in the setting of prevention and extended survival when used to treat advanced tumors, although no durable responses were observed. Conclusions: Our studies point to important contributions of MEK and PI3K signaling to PDAC pathogenesis and suggest that dual targeting of these pathways may provide benefit in some patients with PDAC. Clin Cancer Res; 21(2); 396–404. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-1591

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 144

Metadata

Authors
Alagesan, B., Contino, G., Guimaraes, A. R., Corcoran, R. B., Deshpande, V., Wojtkiewicz, G. R., Hezel, A. F., Wong, K.-K., Loda, M., Weissleder, R., Benes, C., Engelman, J. A., & Bardeesy, N.
Venue
Clinical Cancer Research
Published
2015-01-14
Volume
21
Issue
2
Pages
396-404
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2150090187
Cited by
144
References
10
FWCI
7.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-1591
The paper
Alagesan, B., Contino, G., Guimaraes, A. R., Corcoran, R. B., Deshpande, V., Wojtkiewicz, G. R., Hezel, A. F., Wong, K.-K., Loda, M., Weissleder, R., Benes, C., Engelman, J. A., & Bardeesy, N. (2015). Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-1591

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.